Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02638337
Other study ID # 1517I0231
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date January 26, 2016
Est. completion date July 5, 2017

Study information

Verified date March 2019
Source Shionogi Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this study is to evaluate the efficacy and safety of ospemifene 60 mg once daily (QD) compared with placebo in treatment of vulvo-vaginal atrophy (VVA) due to menopause in women with moderate to severe vaginal dryness as the most bothersome symptom (MBS) of VVA.


Recruitment information / eligibility

Status Completed
Enrollment 631
Est. completion date July 5, 2017
Est. primary completion date June 23, 2017
Accepts healthy volunteers No
Gender Female
Age group 40 Years to 80 Years
Eligibility Inclusion Criteria:

- Subject is postmenopausal.

- Subject has moderate to severe vaginal dryness as the self-reported MBS of VVA.

Exclusion Criteria:

- Subject has clinically significant abnormal findings in the physical examination.

- Subject has a body mass index (BMI) equal to or greater than 38 kg/m^2

- Subject has uncontrolled hypertension.

- Subject has clinically significant abnormal findings in the gynecological examination other than signs of vaginal atrophy.

- Subject has uterine/vaginal bleeding of unknown origin.

- Subject has a vaginal infection requiring medication (may be treated and be eligible for study).

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Ospemifene
60 mg tablet
Placebo
Tablet identical to the ospemifene tablet without drug

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Shionogi

Outcome

Type Measure Description Time frame Safety issue
Primary Change From Baseline in the Percentage of Parabasal Cells in the Maturation Index of the Vaginal Smear at Week 12 Parabasal cells are immature squamous cells in the lining of the vagina. A predominance of parabasal cells indicates absence of estrogenic stimulation and vaginal atrophy.
Vaginal smear samples were taken from the middle third of the lateral vaginal wall and were evaluated at a central laboratory by a qualified pathologist.
A decrease in parabasal cells indicates improvement in vaginal atrophy. To calculate least squares (LS) means, a mixed-effects model for repeated measures (MMRM) model was used.
Baseline and Week 12
Primary Change From Baseline in the Percentage of Superficial Cells in the Maturation Index of the Vaginal Smear at Week 12 Superficial cells are mature squamous cells in the lining of the vagina that can decrease in number after menopause resulting in vulvovaginal atrophy.
Vaginal smear samples were taken from the middle third of the lateral vaginal wall and were evaluated at a central laboratory by a qualified pathologist.
An increase in the number of superficial cells indicates improvement in atrophy.
To calculate least squares (LS) means, a mixed-effects model for repeated measures (MMRM) model was used.
Baseline and Week 12
Primary Change From Baseline in the Vaginal pH at Week 12 The pH scale ranges from 0 to 14. A pH of 7 is neutral, less than 7 is acidic, and greater than 7 is basic. A typical vaginal pH in women of reproductive age is between 3.5 and 4.5, increasing to > 4.5 after menopause.
Vaginal pH was measured by the investigator using a pH indicator strip at the middle third of the vaginal wall.
To calculate least squares (LS) means, a mixed-effects model for repeated measures (MMRM) model was used.
Baseline and Week 12
Primary Change From Baseline in the Severity of Self-reported Most Bothersome Symptom (MBS) of Vaginal Dryness at Week 12 The severity of the most bothersome symptom of vaginal dryness was assessed by the participant through the VVA questionnaire as none = 0, mild = 1, moderate = 2, and severe = 3. Baseline and Week 12
Primary Number of Participants With Adverse Events Treatment-related adverse events (AEs) were defined as AEs that were considered by the investigator to be related to investigational medicinal product, for which causal relationship with the study drug could be reasonably explained.
A serious adverse event (SAE) is defined as any AE occurring at any dose that resulted in any of the following outcomes:
Death
Life-threatening condition
Hospitalization or prolongation of existing hospitalization for treatment
Persistent or significant disability/incapacity
Congenital anomaly/birth defect
Other medically important conditions that, based on medical judgment, may jeopardize the participant's health and may require medical intervention to prevent one of the outcomes listed above.
From the first dose of study drug up to 14 days after the last dose; 14 weeks
Secondary Change From Baseline in the Percentage of Parabasal Cells in the Maturation Index of the Vaginal Smear at Weeks 4 and 8 Parabasal cells are immature squamous cells in the lining of the vagina. A predominance of parabasal cells indicates absence of estrogenic stimulation and vaginal atrophy. Vaginal smear samples were taken from the middle third of the lateral vaginal wall and were evaluated at a central laboratory by a qualified pathologist. A decrease in parabasal cells indicates improvement in vaginal atrophy. Baseline and Weeks 4 and 8
Secondary Change From Baseline in the Percentage of Superficial Cells in the Maturation Index of the Vaginal Smear at Weeks 4 and 8 Superficial cells are mature squamous cells in the lining of the vagina that can decrease in number after menopause resulting in vulvovaginal atrophy. Vaginal smear samples were taken from the middle third of the lateral vaginal wall and were evaluated at a central laboratory by a qualified pathologist. An increase in the number of superficial cells indicates improvement in atrophy. Baseline and Weeks 4 and 8
Secondary Change From Baseline in the Vaginal pH The pH scale ranges from 0 to 14. A pH of 7 is neutral, less than 7 is acidic, and greater than 7 is basic. A typical vaginal pH in women of reproductive age is between 3.5 and 4.5, increasing to > 4.5 after menopause. Vaginal pH was measured by the investigator using a pH indicator strip at the middle third of the vaginal wall. Baseline and Weeks 4 and 8
Secondary Change From Baseline in the Severity of Self-reported Most Bothersome Symptom (MBS) of Vaginal Dryness at Weeks 4 and 8 The severity of the most bothersome symptom of vaginal dryness was assessed by the participant through the VVA questionnaire as none = 0, mild = 1, moderate = 2, and severe = 3. Baseline and Weeks 4 and 8
Secondary Change From Baseline in Vaginal and/or Vulvar Irritation or Itching The severity of vaginal and/or vulvar irritation or itching was assessed by the participant through the VVA questionnaire as none = 0, mild = 1, moderate = 2, and severe = 3. Baseline and Weeks 4, 8, and 12
Secondary Change From Baseline in Difficult or Painful Urination The severity of difficult or painful urination was assessed by the participant through the VVA questionnaire as none = 0, mild = 1, moderate = 2, and severe = 3. Baseline and Weeks 4, 8, and 12
Secondary Change From Baseline in Vaginal Pain Associated With Sexual Activity The severity of vaginal pain associated with sexual activity was assessed by the participant through the VVA questionnaire as none = 0, mild = 1, moderate = 2, and severe = 3. Baseline and Weeks 4, 8, and 12
Secondary Change From Baseline in Vaginal Bleeding Associated With Sexual Activity The severity of vaginal bleeding associated with sexual activity was assessed by the participant through the VVA questionnaire as none = 0, mild = 1, moderate = 2, and severe = 3. Baseline and Weeks 4, 8, and 12
Secondary Change From Baseline in Maturation Value The maturation value is an indicator of the level of maturation attained by the vaginal epithelium.
Vaginal smear samples were taken from the middle third of the lateral vaginal wall and were evaluated at the central laboratory by a qualified pathologist. Parabasal cells (P), intermediary cells (I), and superficial cells (S) were counted and results were expressed as the maturation value (MV), whereby superficial cells were assigned a point value of 1.0, intermediate cells were assigned a point value of 0.5, and parabasal cells were assigned a point value of 0. The maturation value (MV) was defined as:
(percentage of superficial cells * 1) + (percentage of intermediate cells * 0.5) + (percentage of parabasal calls * 0).
Lower MV indicates lower estrogen effect.
Baseline and Weeks 4, 8, and 12
Secondary Percentage of Participants Who Were Responders at Week 4, Week 8, and Week 12 A participant was defined as a responder if all the following conditions were met::
Increase from baseline in maturation value of at least 10
Decrease from baseline in vaginal pH of at least 0.5
Improvement from baseline (decrease in severity) of at least 1 point in the most bothersome symptom of vaginal dryness
Baseline and Weeks 4, 8, and 12
Secondary Change From Baseline in Vaginal Health Index The investigator performed an evaluation of the vagina, assessing overall elasticity, fluid secretion, pH, condition of epithelial mucosa, and moisture. The severity of each characteristic was assessed using a 5-grade scale from 1 (worst) to 5 (best). The total score was calculated as the sum of the 5 individual scores and ranges from 5 to 25, where higher scores indicate better vaginal health Baseline and Weeks 4, 8, and 12
Secondary Change From Baseline in Vulvar Health Index The investigator performed a visual examination of the vulva, assessing the labia majora, labia minora, clitoris, introitus appearance and elasticity, color, discomfort and pain, and presence of other findings (eg, petechiae, excoriations, ulcers, etc). The severity of each characteristic was assessed on a 4-point scale as 0 = normal, 1 = mild, 2 = moderate, and 3 = severe. The total score was calculated by adding the 7 individual scores and ranges from 0 to 21, where lower scores indicate better vulvar health. A negative change from baseline indicates improvement. Baseline and Weeks 4, 8, and 12
Secondary Change From Baseline in Vulvovaginal Imaging Total Score at Week 12 Vulvovaginal imaging was performed by trained site personnel following a standard procedure. Photographs were assessed by an Independent Panel Review (IPR) in a blinded fashion. Nine parameters (labia majora, labia minora, clitoris, urethra, introitus and elasticity, color, erythema, moisture, and other findings (petechiae, excoriation, ulceration, etc.)) were evaluated on a scale from 0 (normal/none) to 3 (severe). The total score was calculated from the sum of the 9 individual scores and ranged from 0 to 27 with lower values indicating better vulvovaginal health; a negative change from baseline indicates improvement. Baseline and Week 12
Secondary Change From Baseline in Female Sexual Function Index Total Score The Female Sexual Function Index consists of 19 questions organized into 6 domains (desire, arousal, lubrication, orgasm, satisfaction, and pain) answered by the participant on a 5-point scale from 1 to 5. Where relevant, some questions also include an option of 0 if a question is not applicable due to no sexual activity. Each domain score was calculated by adding the scores of each item in the domain and multiplying by a domain factor. The total score was calculated by summing each domain score and ranges from 2 to 36, with higher values indicating better sexual function. Baseline and Weeks 4, 8, and 12
Secondary Change From Baseline in Female Sexual Function Index Domain Scores at Week 12 The Female Sexual Function Index consists of 19 questions, organized into 6 domains (desire, arousal, lubrication, orgasm, satisfaction, and pain), answered by the participant on a scale from 1 to 5. Where relevant, some questions also include an option of 0 if not applicable due to no sexual activity. Each domain score was calculated by adding the scores of each item in the domain and multiplying by a domain factor. For all domains, higher values indicate better sexual function, according to the following:
Desire (2 questions): domain score ranges from 1.2 to 6; Arousal (4 questions): domain score ranges from 0 to 6; Lubrication (4 questions): domain score ranges from 0 to 6; Orgasm (3 questions): domain score ranges from 0 to 6; Satisfaction (3 questions): domain score ranges from 0.8 to 6; Pain (3 questions): domain score ranges from 0 to 6.
Baseline and Week 12
Secondary Change From Baseline in Urinary Distress Inventory (UDI)-6 Total Score The presence or absence of urinary symptoms was assessed using the Urinary Distress Inventory (UDI)-6. The symptoms include frequent urination, urine leakage related to the feeling of urgency, urine leakage related to physical activity, coughing, or sneezing, small amounts of urine leakage, difficulty emptying bladder, and pain and discomfort in the lower abdominal or genital area. If a symptom was present, participants were asked to assess the degree to which they were bothered by it on the following 4-point scale:
= present but doesn't bother her at all;
= present and bothers her slightly;
= present and bothers her moderately;
= present and bothers her greatly. The total score was calculated by adding the 6 scores together (Absent = 0), and ranges from 0 to 24, with lower values indicating less urinary distress.
Baseline and Weeks 4, 8, and 12
Secondary Change From Baseline in Bone Sialoprotein at Week 12 Serum bone sialoprotein (BSP) was measured as a marker of bone resorption. Baseline and Week 12
Secondary Change From Baseline in Type I Collagen C-Telopeptide (CTX) at Week 12 Type I collagen C-telopeptide was measured as a marker of bone resorption. Baseline and Week 12
Secondary Change From Baseline in Deoxypyridinoline at Week 12 Deoxypyridinoline was measured as a marker of bone resorption. Baseline and Week 12
Secondary Change From Baseline in Type I Collagen N-Telopeptide (NTX) at Week 12 Type I collagen N-telopeptide was measured as a marker of bone resorption. Baseline and Week 12
Secondary Change From Baseline in Tartrate-Resistant Acid Phosphatase 5b at Week 12 Tartrate-resistant acid phosphatase 5b was measured as a marker of bone resorption. Baseline and Week 12
Secondary Change From Baseline in Alkaline Phosphatase at Week 12 Alkaline phosphatase was measured as a marker of bone formation. Baseline and Week 12
Secondary Change From Baseline in Bone-specific Alkaline Phosphatase at Week 12 Bone-specific alkaline phosphatase was measured as a marker of bone formation. Baseline and Week 12
Secondary Change From Baseline in Osteocalcin at Week 12 Osteocalcin was measured as a marker for bone formation. Baseline and Week 12
Secondary Change From Baseline in Procollagen 1 N-Terminal Propeptide (P1NP) at Week 12 Procollagen 1 N-terminal propeptide was measured as a marker of bone formation. Baseline and Week 12
Secondary Mean Days of Lubricant Use Per Week The mean number of days/week that lubricant was used as documented by participants in an electronic daily diary. Week 1 to Week 12
Secondary Mean Days of Intercourse Per Week The mean number of days/week of intercourse as recorded by participants in an electronic daily diary. Week 1 to Week 12
Secondary Overall Satisfaction With Treatment at Week 12 Participants were asked to record their overall satisfaction with treatment in an electronic diary according to the following categories: Very satisfied, Moderately satisfied, About equally satisfied and dissatisfied, Moderately dissatisfied, and Very dissatisfied. Week 12
Secondary Change From Baseline in Estradiol at Week 12 Baseline and Week 12
Secondary Change From Baseline in Follicle-Stimulating Hormone at Week 12 Baseline and Week 12
Secondary Change From Baseline in Luteinizing Hormone at Week 12 Baseline and Week 12
Secondary Change From Baseline in Sex Hormone-Binding Globulin at Week 12 Baseline and Week 12
Secondary Change From Baseline in Testosterone at Week 12 Baseline and Week 12
Secondary Change From Baseline in Free Testosterone at Week 12 Baseline and Week 12
See also
  Status Clinical Trial Phase
Not yet recruiting NCT01170195 - Effectiveness of Licorice Extract Dietary Supplement on the Treatment of Postmenopausal Symptoms Phase 1/Phase 2
Withdrawn NCT03666819 - Carbon Dioxide Fractional Laser in Treating Participants With Stage 0-III Hormone Receptor-Positive Breast Cancer With Vulvovaginal Atrophy Phase 2
Completed NCT02937805 - Effects of a Moisturizing Cream on Vaginal and Vulvar Mucous Membranes N/A
Completed NCT02994342 - Efficacy and Tolerability Study of ZP-025 Vaginal Gel for the Treatment of Vaginal Dryness N/A
Recruiting NCT05913479 - Evaluation of the Efficacy and Safety of Mucogye® Gel as a Moisturizer N/A
Completed NCT03307044 - Fractional CO2 Laser Therapy for Survivors of Breast Malignancies N/A
Recruiting NCT03714581 - Laser Therapy Following Radiotherapy for Gynecological Cancer N/A
Completed NCT01948583 - Humectant Activity of a New Formulation of Gynomunal® Vaginalgel Phase 4
Completed NCT03178825 - Hybrid Fractional Laser for Symptoms of Genitourinary Syndrome of Menopause N/A
Completed NCT03372720 - Fractional CO2 Laser Therapy in Minimizing Genitourinary Syndrome of Menopause in Gynecological Cancer Survivors N/A
Not yet recruiting NCT06282614 - Performance and Safety of MUCOGYNE® Ovule as a Moisturizer N/A
Completed NCT02176083 - Reproductive Health Survivorship Care Plan Pilot N/A
Completed NCT04908124 - A Clinical Investigation Into the Effectiveness and Safety of Five Water Based Personal Lubricants. Phase 3
Not yet recruiting NCT05156502 - To Assess Signs and Symptoms in Women Affected by GSM After One Cycle of Pixel CO2-Alma Fractionated Laser N/A
Not yet recruiting NCT02987647 - Perception of Efficacy, Safety and Tolerability of Three Non-hormonal Intravaginal Gels and Hormone Cream Phase 4
Not yet recruiting NCT03782961 - Evaluation of Viscosity of a Vaginal Moisturizer Phase 4
Withdrawn NCT01724242 - Vaginal DHEA for Women After Breast Cancer Phase 2/Phase 3
Completed NCT01697345 - Breast Cancer, Aromatase Inhibitor Therapy, and Sexual Functioning: The Effects of Vaginal Testosterone Therapy Phase 0
Completed NCT02269826 - Efficacy and Safety of Non-hormonal Vaginal Preparations in Treating Vaginal Dryness N/A
Completed NCT05644444 - Effectiveness and Safety of a Water-based and a Silicone-based Personal Lubricants With Sensory Action N/A